Search PubMed⌕ Search

Biomedical subjects

M Harms

Publications and source records attributed to M Harms.

At least 73 records · Page 4Linked to original sources
PubMed1988

[Infantile acropustulosis].

Infantile acropustulosis, a dermatosis first described in 1979, is reviewed on the basis of the additional information provided by the 34 new cases that have appeared in the literature since then. This dermatosis of infancy consists of chronically relapsing, highly pruritic pustules, involving the extremities, chiefly the palms and soles. The etiology is unknown. Sulfones are the only effective form of therapy, but they have many side-effects and their use is only rarely indicated in this benign disease. The differential diagnosis, including many other pustular eruptions of infancy, is discussed in detail.

Diagnosis, Differential↗
PubMed1988

[Malignant lymphoma of parotid origin mimicking Melkersson-Rosenthal syndrome].

The Melkersson-Rosenthal syndrome is classically described as the association of a unilateral tumefaction, a facial hemiparesia and of a furrowing of the tongue. Granulomatous blepharitis is an unusual localisation of the facial tumefaction, and chronic periocular oedema may represent a difficult differential diagnosis. The reported case has erroneously been diagnosed as a Melkersson-Rosenthal syndrome and further showed to be a parotid gland involvement of a systemic malignant lymphoma.

Diagnosis, Differential↗
PubMed1987

[Intracranial pressure-controlled treatment of brain edema with glycerin and sorbitol in intracerebral hemorrhage].

The continuous epidural registration of intracerebral pressure showed that the pronounced brain edema which develops during the 4th to 14th day of an intracerebral hemorrhage could lead to an increase in intracerebral pressure (ICP greater than 25 mmHg) requiring treatment. During the therapy extensive ICP crises (ICP greater than 35 mmHg), lasting for 1 to 3 days and only controllable through high doses of glycerol and sorbitol, developed. Glycerol (50 g orally) and sorbitol (50 g i.v.) lowered the pressure during this phase for approximately 3 h and 1.5 h respectively. These time intervals were in accordance with the changes in plasma osmolality through the administration of both substances. Due to its longer efficacy, glycerol provides an important supplement or alternative to sorbitol therapy, especially as the permitted maximum dosage would have to have been exceeded in a treatment consisting exclusively of sorbitol. The duration of the decrease in intracerebral pressure lasted longer during the remainder of the treatment in the case of both substances, being decisively dependent on the intracerebral pressure intensity. The relatively harmless epidural measurement of intracerebral pressure allowed an optimal control of the brain edema therapy as the dosage of the hyperosmolar substances could be given exactly in accordance with the intracerebral pressure intensity and subsequently varying efficacy.

Administration, Oral↗
PubMed1986

The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study.

89 patients (66 males and 23 females) with severe acne were treated with isotretinoin and were followed up for a period of 6-47 months (mean 14 months) after the end of the therapy. Relapses occurred in 14.6% of the patients. They were not found to be related to the total amount of isotretinoin administered (up to 233 mg/kg); a possible, although not significant, link to sex was observed since relapses occurred in 16.6% males and 8.6% of females. But the age of the patients had a significant bearing on the likelihood of relapses: younger patients relapsed more frequently than older patients.

Acne Vulgaris↗
PubMed1986

Arotinoid Ro 13-6298 and etretin: two new retinoids inferior to isotretinoin in sebum suppression and acne treatment.

Thirty patients have been treated with either etretin, the main derivative of etretinate, or arotinoid Ro 13-6298, a polyaromatic retinoid, or isotretinoin. Sebum production was measured before and during the treatments. While no change was observed in the patients treated with etretin, a reduction of 33% of the sebum excretion rate was observed for those treated with arotinoid Ro 13-6298 but only after long treatment periods of 20 to 30 weeks. The sebum excretion rate decreased by 92% in the patients treated with isotretinoin. Four patients suffering from severe nodulocystic acne were treated with arotinoid Ro 13-6298 for 2-5 months without improvement. Substantial improvement, however, resulted after a subsequent treatment with isotretinoin; sebum production decreased markedly as well. This study suggests that neither etretin nor arotinoid Ro 13-6298 will replace isotretinoin in the treatment of severe nodulocystic acne.

Acitretin↗
PubMed1984

KID syndrome (keratitis, ichthyosis, and deafness) and chronic mucocutaneous candidiasis: case report and review of the literature.

In 1981 Skinner et al (1) proposed the term KID syndrome for a previously disparate group of congenital disorders principally made up of keratitis (K), ichthyosis (I), and deafness (D). The coexistence of congenital deafness associated with ichthyosis had been previously recognized (2,3), yet similarities among affected patients were overlooked because of both the paucity of cases and their seeming diversity. The patient reported by Skinner is similar to one whom we have been following at the Clinique Universitaire de Dermatologie in Geneva since 1978. After having reviewed the literature, we believe that KID syndrome is a useful, unifying clinical term.

Adolescent↗
PubMed1983

[Treatment of acne with orally administered isotretinoin. Clinical study of 56 patients].

56 patients with nodulocystic acne, hidrosadenitis (2 cases) and steatocystoma multiplex (2 cases) were treated with oral isotretinoin. 52 patients cleared completely or were much improved without local treatment; 2 failures involved patients with steatocystoma, while 2 patients with ano-inguinal lesions were only improved. 19 patients received a dose of 0.5 mg/kg/day for six months; in 37 patients the dose was adapted to the initial response but did not exceed 1 mg/kg/day. Reversible elevated triglyceride concentration was observed in 5% of the patients. 18 patients were followed up and 4 (22%) presented moderate relapses.

Acne Vulgaris↗